Cantor Fitzgerald raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $38 from $32 and keeps a Neutral rating on the shares. The strong quarter on TAVALISSE $44.7M proved that the strong uptick we saw in Q3 wasn’t a one-time fluke, the analyst tells investors in a research note. The firm thinks the pipeline opportunity deserves “equal attention” in light of the trends from TAVALISSE in 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL: